MX2012000316A - Anticuerpos humanizados para el receptor 2 tipo toll y usos de los mismos. - Google Patents
Anticuerpos humanizados para el receptor 2 tipo toll y usos de los mismos.Info
- Publication number
- MX2012000316A MX2012000316A MX2012000316A MX2012000316A MX2012000316A MX 2012000316 A MX2012000316 A MX 2012000316A MX 2012000316 A MX2012000316 A MX 2012000316A MX 2012000316 A MX2012000316 A MX 2012000316A MX 2012000316 A MX2012000316 A MX 2012000316A
- Authority
- MX
- Mexico
- Prior art keywords
- toll
- receptor
- amino acid
- acid sequence
- sequence
- Prior art date
Links
- 102000008228 Toll-like receptor 2 Human genes 0.000 title abstract 3
- 108010060888 Toll-like receptor 2 Proteins 0.000 title abstract 3
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 3
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 230000011664 signaling Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Abstract
Un anticuerpo completamente humanizado que tiene especificidad de unión al Receptor 2 tipo Toll comprende una cadena ligera y una cadena pesada completamente comprenda de la secuencia de aminoácidos de origen humano. La región variable de la cadena ligera comprende una secuencia de aminoácidos que es sustancialmente homóloga con la secuencia de SEQ ID NO:1, en donde la región variable del dominio pesado comprende una secuencia de aminoácidos que es sustancialmente homóloga con la secuencia de SEQ ID NO:4. También se proporcionan ácidos nucleicos que codifican para estos anticuerpos, así como el uso de los anticuerpos en medicina, en particular para el tratamiento de enfermedades inflamatorias y autoinmunitarias que se medían por la señalización y activación del Receptor 2 tipo Toll.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US27023909P | 2009-07-06 | 2009-07-06 | |
IE20090514A IE20090514A1 (en) | 2009-07-06 | 2009-07-06 | Humanised antibodies and uses therof |
PCT/EP2010/059677 WO2011003925A1 (en) | 2009-07-06 | 2010-07-06 | Humanised antibodies to toll-like receptor 2 and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2012000316A true MX2012000316A (es) | 2012-04-20 |
Family
ID=43428820
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2012000316A MX2012000316A (es) | 2009-07-06 | 2010-07-06 | Anticuerpos humanizados para el receptor 2 tipo toll y usos de los mismos. |
Country Status (16)
Country | Link |
---|---|
US (1) | US8734794B2 (es) |
EP (2) | EP2451842B1 (es) |
JP (2) | JP5847707B2 (es) |
KR (1) | KR101572171B1 (es) |
CN (1) | CN102482356B (es) |
AU (1) | AU2010270241B2 (es) |
BR (1) | BRPI1014016B8 (es) |
CA (1) | CA2766996C (es) |
ES (2) | ES2488615T3 (es) |
IE (1) | IE20090514A1 (es) |
IL (1) | IL217225A (es) |
IN (1) | IN2012DN00938A (es) |
MX (1) | MX2012000316A (es) |
NZ (2) | NZ597447A (es) |
RU (1) | RU2563344C2 (es) |
WO (1) | WO2011003925A1 (es) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201205633D0 (en) | 2012-03-30 | 2012-05-16 | Opsona Therapeutics Ltd | Toll-like receptor 2 binding epitope and binding members thereto |
US10047164B2 (en) | 2012-10-19 | 2018-08-14 | Opsona Therapeutics Limited | Methods and compositions for the treatment of pancreatic cancer |
EP2722342A1 (en) | 2012-10-19 | 2014-04-23 | Opsona Therapeutics Limited | Methods and compositions for the treatment of pancreatic cancer |
KR101478426B1 (ko) | 2013-02-08 | 2014-12-31 | 아주대학교산학협력단 | 톨 유사 수용체 2를 포함하는 백질 뇌졸중 검출용 바이오마커 및 톨 유사 수용체 2의 의학적 용도 |
JP6366195B2 (ja) * | 2013-04-22 | 2018-08-01 | 国立大学法人 東京大学 | 炎症性疾患の予防又は治療剤 |
CN103319600B (zh) * | 2013-06-19 | 2014-12-17 | 南京军区军事医学研究所 | 一种人源抗TLR4抗体Fab及其制备方法与应用 |
CN106062193B (zh) * | 2014-02-28 | 2020-08-25 | 安斯泰来制药株式会社 | 与人tlr2及人tlr4结合的双特异性抗体 |
CN104403001B (zh) * | 2014-12-12 | 2018-01-16 | 中国人民解放军南京军区军事医学研究所 | 一种全人源抗TLR4的抗体Fab及其全分子抗体IgG和应用 |
TWI703156B (zh) | 2015-01-30 | 2020-09-01 | 學校法人埼玉醫科大學 | 抗alk2抗體 |
FR3048971A1 (fr) * | 2016-03-15 | 2017-09-22 | Univ Rabelais Francois | Constructions peptidiques bispecifiques et leur utilisation dans le traitement de maladies notamment imflammatoires |
JP7220654B2 (ja) * | 2016-12-02 | 2023-02-10 | ニューレメディ カンパニー リミテッド | 骨髄異形成症候群の治療のための組成物および方法 |
EP4095228A1 (en) * | 2016-12-22 | 2022-11-30 | Avectas Limited | System for vector-free intracellular delivery by reversible permeabilisation |
US11634495B2 (en) | 2017-04-07 | 2023-04-25 | Miltenyi Biotec B.V. & Co. KG | Methods of activating CD32b/c comprising administering an antibody that binds BDCA-2 (CD303) |
CN111868084B (zh) * | 2018-01-29 | 2024-03-22 | 加利福尼亚大学董事会 | 治疗tlr2介导的疾病和病症的疗法和方法 |
EP3583949A1 (en) | 2018-06-19 | 2019-12-25 | Opsona Therapeutics Limited | Toll-like receptor 2 (tlr2) antagonists for the treatment of ovarian cancer |
KR20200050715A (ko) * | 2018-11-02 | 2020-05-12 | 주식회사 젠센 | Tlr 억제 펩타이드를 포함하는 루푸스 예방 또는 치료용 조성물 |
CN111109198B (zh) * | 2019-03-29 | 2021-08-20 | 成都华西海圻医药科技有限公司 | 一种葡萄膜炎动物模型构建方法 |
CN111393530A (zh) * | 2020-03-30 | 2020-07-10 | 中国人民解放军南部战区总医院 | 新人源tlr2胞外区段单克隆抗体及其制备方法和应用 |
WO2023154799A1 (en) | 2022-02-14 | 2023-08-17 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Combination immunotherapy for treating cancer |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
AU634186B2 (en) | 1988-11-11 | 1993-02-18 | Medical Research Council | Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors |
US6291158B1 (en) | 1989-05-16 | 2001-09-18 | Scripps Research Institute | Method for tapping the immunological repertoire |
CA2110799A1 (en) | 1991-06-14 | 1992-12-23 | Arnold H. Horwitz | Microbially-produced antibody fragments and their conjugates |
ES2227512T3 (es) | 1991-12-02 | 2005-04-01 | Medical Research Council | Produccion de anticuerpos contra auto-antigenos a partir de repertorios de segmentos de anticuerpos fijados en un fago. |
SE9400088D0 (sv) | 1994-01-14 | 1994-01-14 | Kabi Pharmacia Ab | Bacterial receptor structures |
DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
GB9927332D0 (en) * | 1999-11-18 | 2000-01-12 | Leiv Eiriksson Nyfotek As | Novel antibody and uses thereof |
ATE448301T1 (de) | 2000-09-08 | 2009-11-15 | Univ Zuerich | Sammlung von proteinen mit sich wiederholenden sequenzen (repeat proteins), die repetitive sequenzmodule enthalten |
US20030157561A1 (en) | 2001-11-19 | 2003-08-21 | Kolkman Joost A. | Combinatorial libraries of monomer domains |
US20050089932A1 (en) | 2001-04-26 | 2005-04-28 | Avidia Research Institute | Novel proteins with targeted binding |
US20050053973A1 (en) | 2001-04-26 | 2005-03-10 | Avidia Research Institute | Novel proteins with targeted binding |
CN1809357B (zh) * | 2003-06-20 | 2010-12-22 | 科勒制药有限公司 | 小分子Toll样受体(TLR)拮抗剂 |
US7388080B2 (en) | 2003-08-20 | 2008-06-17 | University Of Massachusetts | Selective inhibition of toll-like receptor-2 |
EP1664118B1 (en) * | 2003-09-23 | 2011-05-25 | Technische Universität München | Tlr2 antagonistic antibody and use thereof |
CA2543360A1 (en) | 2003-10-24 | 2005-05-06 | Joost A. Kolkman | Ldl receptor class a and egf domain monomers and multimers |
SG158098A1 (en) * | 2004-11-30 | 2010-01-29 | Centocor Inc 22 30 74 Date Of | Toll like receptor 3 antagonists, methods and uses |
AU2006210724A1 (en) | 2005-02-03 | 2006-08-10 | Antitope Limited | Human antibodies and proteins |
EP1929073A4 (en) | 2005-09-27 | 2010-03-10 | Amunix Inc | PROTEIN MEDICAMENT AND ITS USE |
PT1989544E (pt) | 2006-03-02 | 2011-09-26 | Antitope Ltd | Ensaios com células t |
CA2689680C (en) * | 2007-05-14 | 2017-11-07 | Novimmune Sa | Fc receptor-binding polypeptides with modified effector functions |
EP2170366B1 (en) * | 2007-08-03 | 2013-11-06 | Opsona Therapeutics Limited | Use of tlr-2 antagonists for treatment of reperfusion injury and tissue damage |
-
2009
- 2009-07-06 IE IE20090514A patent/IE20090514A1/en not_active IP Right Cessation
-
2010
- 2010-07-06 BR BRPI1014016A patent/BRPI1014016B8/pt active IP Right Grant
- 2010-07-06 KR KR1020127003134A patent/KR101572171B1/ko active IP Right Grant
- 2010-07-06 NZ NZ597447A patent/NZ597447A/en unknown
- 2010-07-06 ES ES10728262.6T patent/ES2488615T3/es active Active
- 2010-07-06 CN CN201080035690.4A patent/CN102482356B/zh active Active
- 2010-07-06 EP EP10728262.6A patent/EP2451842B1/en active Active
- 2010-07-06 WO PCT/EP2010/059677 patent/WO2011003925A1/en active Application Filing
- 2010-07-06 RU RU2011153932/10A patent/RU2563344C2/ru active
- 2010-07-06 IN IN938DEN2012 patent/IN2012DN00938A/en unknown
- 2010-07-06 JP JP2012518974A patent/JP5847707B2/ja active Active
- 2010-07-06 US US13/382,044 patent/US8734794B2/en active Active
- 2010-07-06 NZ NZ615441A patent/NZ615441A/en unknown
- 2010-07-06 CA CA2766996A patent/CA2766996C/en active Active
- 2010-07-06 ES ES14158199.1T patent/ES2658224T3/es active Active
- 2010-07-06 AU AU2010270241A patent/AU2010270241B2/en active Active
- 2010-07-06 EP EP14158199.1A patent/EP2805973B1/en active Active
- 2010-07-06 MX MX2012000316A patent/MX2012000316A/es active IP Right Grant
-
2011
- 2011-12-27 IL IL217225A patent/IL217225A/en active IP Right Grant
-
2015
- 2015-08-28 JP JP2015169427A patent/JP6677466B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
JP6677466B2 (ja) | 2020-04-08 |
JP2016025863A (ja) | 2016-02-12 |
IE20090514A1 (en) | 2011-02-16 |
IN2012DN00938A (es) | 2015-04-03 |
US8734794B2 (en) | 2014-05-27 |
ES2488615T3 (es) | 2014-08-28 |
BRPI1014016B8 (pt) | 2020-05-19 |
WO2011003925A1 (en) | 2011-01-13 |
BRPI1014016B1 (pt) | 2020-04-07 |
EP2805973A3 (en) | 2015-03-04 |
RU2563344C2 (ru) | 2015-09-20 |
RU2011153932A (ru) | 2013-08-20 |
AU2010270241B2 (en) | 2015-02-19 |
BRPI1014016A2 (pt) | 2016-09-13 |
ES2658224T3 (es) | 2018-03-08 |
EP2805973A2 (en) | 2014-11-26 |
EP2451842A1 (en) | 2012-05-16 |
JP2012531922A (ja) | 2012-12-13 |
KR101572171B1 (ko) | 2015-11-26 |
CA2766996A1 (en) | 2011-01-13 |
NZ597447A (en) | 2013-12-20 |
AU2010270241A1 (en) | 2012-02-02 |
NZ615441A (en) | 2014-10-31 |
CN102482356A (zh) | 2012-05-30 |
KR20120075457A (ko) | 2012-07-06 |
CA2766996C (en) | 2017-08-01 |
IL217225A0 (en) | 2012-02-29 |
EP2805973B1 (en) | 2017-11-08 |
EP2451842B1 (en) | 2014-05-14 |
US20120164159A1 (en) | 2012-06-28 |
CN102482356B (zh) | 2016-05-25 |
IL217225A (en) | 2017-08-31 |
JP5847707B2 (ja) | 2016-01-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2012000316A (es) | Anticuerpos humanizados para el receptor 2 tipo toll y usos de los mismos. | |
NZ599140A (en) | Antibodies that specifically bind to the epha2 receptor | |
MY183134A (en) | Anti-cemx antibodies capable of binding to human mlge on b lymphocytes | |
NZ601271A (en) | Cd127 binding proteins | |
EA201400568A1 (ru) | Альбуминсвязывающие антитела и их связывающие фрагменты | |
NZ607969A (en) | Cd33 binding agents | |
MX2010009190A (es) | Anticuerpos anti-c5ar humanizados. | |
GB201112429D0 (en) | Antigen-binding proteins with increased FcRn binding | |
NZ603499A (en) | Human cytomegalovirus neutralizing antibodies and uses thereof | |
NZ703653A (en) | Anti-fap antibodies and methods of use | |
NZ597692A (en) | Anti-IGF antibodies | |
EA201790757A1 (ru) | Связывающие антиген cd27l белки | |
NZ612512A (en) | Use of chimeric antigen receptor-modified t cells to treat cancer | |
WO2010017103A3 (en) | Fully human anti-human nkg2d monoclonal antibodies | |
PE20191408A1 (es) | Proteinas de union a antigeno st2 | |
NZ602892A (en) | Antibodies that bind human cd27 and uses thereof | |
MX348360B (es) | Anticuerpo biespecifico psmaxcd3 de simple cadena especifico de especies cruzadas. | |
PE20121361A1 (es) | Antagonistas de pcsk9 | |
NZ589436A (en) | Dual variable domain immunoglobulins and uses thereof | |
TN2011000528A1 (en) | Compositions and methods for antibodies targeting complement protein c3b | |
MX361929B (es) | Anticuerpos anti-ligando de quimiocina cc 20 (ccl20) neutralizantes. | |
NZ612312A (en) | Her2 binding peptides labeled with aluminium-[18] fluoride complexed by nota | |
NZ594682A (en) | Fully human antibodies specific to cadm1 | |
NZ629553A (en) | Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof | |
NZ610091A (en) | Antibodies |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |